SciGen partner increases investment
Friday, 04 November, 2005
The two largest shareholders in Singapore-based, ASX-listed biopharmaceutical company SciGen (ASX:SIE), SciTech Medical and Bioton, have entered into a share exchange agreement which may result in Bioton gaining a 44.7 per cent equity share in SciGen.
Under the agreement between Polish company Bioton and Singapore private healthcare company SciTech, Bioton will invest AUD$30 million to accelerate the launch of SciGen's portfolio of biopharmaceutical products to market.
SciTech is selling its shares to Bioton for $0.075 per SciGen share, a premium to the ASX market price of $0.067 at close of trading on Friday 28 October when the deal was entered into.
Saul Mashaal will remain as SciGen's executive vice-chairman and CEO, and will be elected to the supervisory board of Bioton.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
